{
    "name": "diflorasone",
    "comment": "Rx",
    "other_names": [
        "Psorcon",
        "ApexiCon",
        "ApexiCon E"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/apexicon-e-diflorasone-343517",
    "pregnancy": {
        "common": [
            "Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels; more potent corticosteroids shown to be teratogenic after dermal application in laboratory animals; there are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids; topical corticosteroids should be used during pregnancy only if potential benefit justifies potential risk to fetus; drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk; because many drugs are excreted in human milk, exercise caution should when administering product to a nursing woman"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Underlying infection",
                "Hypersensitivity",
                "Ophthalmic use"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Chronic topical corticosteroid therapy may interfere with growth and development in children",
                "Use med to very high potency for <2 wk to reduce local and systemic side effects",
                "Use low potency for chronic therapy",
                "Kaposi's sarcoma reported with prolonged corticosteroid therapy ",
                "Avoid medium to very high potency on face, folds, groin because can increase steroid absorption",
                "Use lower potency for children (ie, increase BSA/kg, therefore increase systemic absorption)",
                "Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma; cataracts reported in postmarketing experience with use of topical diflorasone diacetate products; glaucoma, with possible damage to optic nerve, and increased intraocular pressure reported in postmarketing experience with use of topical dermal corticosteroids",
                "Avoid contact with eyes; advise patients to report any visual symptoms",
                "Some patients, including children may exhibit susceptibility to corticosteroid-induced HPA axis suppression and Cushing's syndrome due to prolonged use, or addition of occlusive dressings",
                "Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity",
                "If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted",
                "In presence of dermatological infections, institute appropriate antifungal or antibacterial; if a favorable response does not occur promptly, the discontinue corticosteroid therapy until infection has been adequately controlled"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Skin atrophy",
            "percent": "2"
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Dryness",
            "percent": null
        },
        {
            "name": "Folliculitis",
            "percent": null
        },
        {
            "name": "Secondary infection",
            "percent": null
        },
        {
            "name": "Striae",
            "percent": null
        },
        {
            "name": "Pigmentation changes",
            "percent": null
        },
        {
            "name": "HPA suppression",
            "percent": null
        },
        {
            "name": "with higher potency used",
            "percent": null
        },
        {
            "name": "wk",
            "percent": null
        },
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Irritation",
            "percent": null
        },
        {
            "name": "Hypertrichosis",
            "percent": null
        },
        {
            "name": "Acneiform eruptions",
            "percent": null
        },
        {
            "name": "Hypopigmentation",
            "percent": null
        },
        {
            "name": "Perioral dermatitis",
            "percent": null
        },
        {
            "name": "Allergic contact dermatitis",
            "percent": null
        },
        {
            "name": "Maceration of the skin",
            "percent": null
        },
        {
            "name": "Miliaria",
            "percent": null
        },
        {
            "name": "Vision Disorders",
            "percent": null
        },
        {
            "name": "Cataract",
            "percent": null
        },
        {
            "name": "glaucoma",
            "percent": null
        },
        {
            "name": "central serous chorioretinopathy",
            "percent": null
        }
    ]
}